"Designing Growth Strategies is in our DNA"

Oncology Biosimilars Market Size, Share And Global Trend By Drug Class (mAb, G-CSF, Hematopoietic Agents, Others), By Type of Cancer (Lung Cancer, Breast Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Blood Cancer, Brain Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And Geography Forecast Till 2026

In January 2019, the FDA approved the third ever oncology biosimilar called Ontruzant (trastuzumab-dttb) of Samsung Bioepis which is a Herceptin referencing biosimilar tr... Read More

Final report will be updated to address the impact of COVID-19 on this particular market

Region : Global | Published Date: Upcoming | Report ID: FBI100578 | Status : Upcoming

 

Request PDF Brochure

Refresh Button
Oncology Biosimilars Market Size, Share and Global Industry Trend Forecast till 2025
  • PDF
  • 2018
  • 2014-2018
  • Choose License Type
  • 4850
    6850
    8850

Healthcare Clients

DUPONT
Abbott
baxter
lpsos
Logo_Merck_KGaA_2015
chong-kun-dang
DAEWOONG
Natus-Medical
SUANFARMA
Bio-Rad
Intuitive_Surgical_logo
novo-nordisk
Ge-Healthcare
Sedana-Cyan-Black-Tag






We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X